Skip to main content
Cureus logoLink to Cureus
. 2017 Feb 17;9(2):e1038. doi: 10.7759/cureus.1038

Does Vitamin D Deficiency Lead to Hypertension?

Varshil Mehta 1,, Shivika Agarwal 2
Editors: Alexander Muacevic, John R Adler
PMCID: PMC5356990  PMID: 28357170

Abstract

Hypertension (HTN) or high blood pressure is one of the most chronic and deadliest disorders in the world. There are many risk factors responsible for HTN which include age, race, using tobacco, high salt intake, etc. One of the risk factors we would like to highlight is low vitamin D levels. While there is strong evidence that Vitamin D plays an important role in maintaining bone and muscle health, there has been recent debate regarding its role in hypertension. However, there are many studies that have shown an indirect relation between 25-hydroxyvitamin D serum level and blood pressure. However, we suggest that more studies, especially randomised trials, should be conducted.

Keywords: risk factor, htn, vitamin supplementation, 25-hydroxy vitamin d

Introduction and background

Hypertension or increase in blood pressure has been considered as one of the leading factors in causing worldwide disability-adjusted life years [1]. HTN has many etiological factors, which include age, race, family history, obesity, sedentary lifestyle, using tobacco, high salt intake, stress, and consuming alcohol in a larger quantity [2]. 

One of the recent studies by Kearney, et al. showed that more than one billion adults worldwide (approximately 25%) are suffering from HTN, and there is a possibility that this number will climb up to 29% by 2025 [3]. The prevalence rate of HTN among Iranian people aged 30 to 55 years old and those over 55 years old is approximately 23% and 50%, respectively [4].

Hypertension is considered as the fundamental reason for mortality on the planet, the most well-known reason for going to a doctor, and the least complex treatable and recognisable risk factor for diseases like cerebrovascular accident (CVA), myocardial infarction (MI), congestive heart failure (CHF), peripheral artery disease (PAD), atrial fibrillation (AF), and end-stage renal disease (ESRD) [5-6].

Regardless of solid archives showing the reality that treatment of hypertension will diminish the casualty significantly, hypertension is not treated or not totally treated in the vast majority of patients experiencing this issue in entire nations, including nations profiting from the most advanced therapeutic care frameworks. For this reason, hypertension is considered as one of the fundamental general medical problems [7].

In some observational reviews, it has been recognized that hypertension is more prevalent amid chilly months of a year as well as in zones that are a long way from the equator where sun radiation is reduced. For every 10 degrees of deviation from the equator, blood pressure and hypertension will rise 2.5 mm Hg and 2.5%, respectively [8-10].

More than 40% of African-Americans in the US experience hypertension while just 25% of white Americans have such an issue. African-Americans are prone to more severe and earlier hypertension, which further damages target organs and, subsequently, leads to premature disability and death [5, 11-12]. By this issue, we know that the decline in ultraviolet (UV) radiation, and henceforth, the decrease in the skin's capacity for Vitamin D synthesis, can have a connection with hypertension.

Krause, et al. utilized ultraviolet-B (UVB) light to treat patients with untreated mild essential hypertension (EH) and a deficiency of Vitamin D. These scientists found that UVB radiation, not UVA radiation, led to an increase in 25-hydroxyvitamin D (25(OH)D) levels and brought down blood pressure (BP) in Vitamin D-deficient patients with EH. Since 1998, this finding has brought extensive research enthusiasm up in the relationship between vitamin D inadequacy and EH [13].

Mehta suggested that low levels of Vitamin D, along with sugar and fats, should be considered as new risk factors in causing hypertension [14]. This article will bring forward the importance of Vitamin D and its role in maintaining blood pressure levels.

Review

Association of Vitamin D levels and hypertension

Ultraviolet-B from the sun prompts the development of pre-vitamin D3 from 7-hydrocholesterol in the skin, which then undergoes thermal isomerisation to form vitamin D3. It later undergoes hydroxylation to form 25-hydroxyvitamin D (25(OH)D) (by the action of 25-hydroxyvitamin-D-hydroxylase) in the liver and subsequently gets converted to 1,25-dihydroxyvitamin D3 (1,25 (OH2)D3) in the kidneys, blood vessels, and heart as shown in Figure 1 [15].

Figure 1. Role of Vitamin D in Maintaining Blood Pressure (15).

Figure 1

Many tissues and organs express VDR, including the heart, endothelium, vascular smooth muscle, and T cells [16-19].

VDR is a nuclear receptor to which Vitamin D3 (VD3) binds with high affinity and specificity. When bound with VD3, VDR is phosphorylated, which leads to a surface conformational change. This VDR is now activated and interacts with the retinoid X receptor (RXR) eventually forming a heterodimer that binds to Vitamin D-responsive elements in the region of gene promoter [20-21].

By recruiting either corepressors or coactivator complexes [22-23], activated VDR/RXR regulates the gene transcription for protein synthesis that modulates the traditional and non-traditional functions of VD3 (e.g., musculoskeletal health, calcium homeostasis, and normal BP and cardiovascular function) [24-25].

Along these lines, we can say that the role of Vitamin D in a cell, tissue, or organ relies on the local production or an adequate measure of VD3, expression levels of VDR/RXR and co-receptor proteins, and cell-specific transcriptional elements to manage genes that encode proteins altering Vitamin D signaling.

Previous clinical studies

Kota, et al. demonstrated that systolic blood pressure, diastolic blood pressure, and mean arterial pressure had increased among individuals experiencing inadequacy of Vitamin D and proposed that Vitamin D deficiency is associated with renin-angiotensin-aldosterone system (RAAS) regulation [26]. One comparable review demonstrated that individuals with larger amounts of Vitamin D had lower blood pressure and a lower danger of developing hypertension [27].

A study done in 2013 took into account many reviews that included individuals with hypertension. They found that for every 10 ng/ml increment in Vitamin D levels, a 12% lower danger of developing hypertension was observed. The general population with the most noteworthy Vitamin D levels had a 30% lower danger of developing hypertension contrasted with the general population with the least levels. In any case, the greater part of the reviews was done in the United States, implying that we cannot know without a doubt if the outcomes would be the same in different countries [28].

A few studies have taken into account of the impact of Vitamin D on blood pressure in individuals who have hypertension. One such meta-analysis found out that taking Vitamin D supplementation could bring down systolic blood pressure [29].

A study by Jorde, et al. in 2010 exhibited a connection between low serum Vitamin D levels and hypertension. However, no confirmation was discovered showing that a Vitamin D prescription would have the capacity to prevent hypertension in the future [30].

A group of scientists studied the effect of taking a Vitamin D supplement on the risk of hypertension in African-Americans who had normal blood pressure was studied in 2013. These scientists appointed 250 individuals to get either 1,000 IU every day, 2,000 IU every day, 4,000 IU every day, or a placebo for three months. They discovered that for every increase in Vitamin D supplementation and Vitamin D levels in the body, systolic blood pressure declined; however, the diastolic pressure remained the same [31].

An experiment in 2012 in Denmark looked at the effects of Vitamin D supplements on lowering blood pressure in people with hypertension. For 20 weeks, people either took 3,000 IU per day of Vitamin D or a placebo pill. The researchers measured a few different types of blood pressure and found that the people in the Vitamin D group lowered their blood pressure more than the people getting the placebo. People in the Vitamin D group who had low levels of Vitamin D at the beginning of the study had a bigger reduction in their blood pressures. Vitamin D may be more effective in lowering blood pressure in people who have low levels of Vitamin D [32].

An Italian study conducted by Carrara, et al. in 2013 reviewed the role of Vitamin D supplementation on regulating the BP in the body. A group of hypertensives was given 25,000 IU per week of Vitamin D for a total of eight weeks. They found out that Vitamin D levels increased throughout the study and BPs were greatly reduced. Hence, they concluded that an overactive blood pressure system can lead to higher blood pressure and Vitamin D may help to reduce the risk of hypertension [33].

To test whether 25(OH)D levels are significantly associated with blood pressure and HTN risk, Vimaleswaran, et al. conducted a study (Mendelian randomization) and used different variants of genes that affect 25(OH)D synthesis or substrate availability (Vitamin D 25-hydroxylase and 7-dehydrocholesterol reductase) to meta-analyse 146,581 participants. They found out that each 10% increment in genetically instrumented 25(OH)D concentration was associated with a decrease in systolic BP (-0.37 mmHg, P = 0.052) and diastolic BP (-0.29 mmHg, P = 0.01), and an 8.1% reduced odds of HTN (P = 0.002). The findings of a study conducted later, further confirmed that increased 25(OH)D concentrations might decrease the risk of HTN [34-35].

Caro, et al. concluded that serum 25(OH) Vitamin D levels do not have any significant statistical association with blood pressure [36]. In 2008, an experiment used data from a large experiment that assigned women to receive either 1-gram per day of calcium, plus 400 IU per day of Vitamin D, or a placebo pill. They observed that there was no significant difference in blood pressure changes between both the groups [37].

It was shown in a review done by Lee, et al. that serum Vitamin D and parathyroid hormone (PTH) levels have no significant connection in relation to hypertension among Chinese individuals [38]. In a cross-sectional review of 251 individuals (age 40 or more years old) by Kashi, et al., it was discovered that there was no association between hypertension and serum 25(OH) Vitamin D, calcium, and PTH levels [39].

Some other unknown elements might have an impact on the relation between Vitamin D and hypertension, especially in older age groups, as Sanijder reported in his review, which showed Vitamin D effect’s on blood pressure might be indirectly based on its role in parathyroid hormone performance [40]. The comparison and findings of all the studies are presented in Table 1.

Table 1. Comparison and Findings of the Studies.

25(OH)D: 25-hydroxyvitamin D; HTN: hypertension

Author Year of Publication N Mean Age (Years) Mean 25(OH)D (ng/ml) Mean Systolic Blood Pressure (mm/Hg) Mean Diastolic Blood Pressure (mm/Hg) Findings
Kota, et al. [26] 2011 50 49.5 ± 7.8 18.5 ± 6.4 162.4 ± 20.2 100.2 ± 11.2 Lower 25(OH)D levels associated with increased blood pressure
Ullah, et al. [27] 2010 - - - - - Larger 25(OH)D levels associated with lower blood pressure
Kunutsor, et al. [28] 2013 - - - - - Larger 25(OH)D levels associated with lower chances to develop HTN
Witham, et al. [29] 2009 - - - - - Larger 25(OH)D levels associated with lower chances to develop HTN
Jorde, et al. [30] 2010 4,125 - - - - No association between 25(OH)D and HTN
Forman, et al. [31] 2007 117,730 - - - - Larger 25(OH)D levels associated with lower chances to develop HTN
Larsen, et al. [32] 2012 112 61 ± 10 23 ± 10 Decreased by 7 mmHg after taking Vitamin D supplementation in 24 hrs vs. placebo Decreased by 2 mmHg after taking Vitamin D supplementation vs. placebo Vitamin D supplementation in patients with low levels of 25(OH)D brings down blood pressure
Carrara, et al. [33] 2013 15 43.6 ± 21.6 18.3 ± 2.8 At 0 week: 137.4 ± 1.8 At 0 week: 81.6 ± 1.8 Vitamin D supplementation in patients with low levels of 25(OH)D brings down blood pressure
At 8 weeks (after Vitamin D supplementation): 134.8 ± 2.3 At 8 weeks: 81.0 ± 1.6
Vimaleswaran, et al. [34] 2014 146,581 - - - - Larger 25(OH)D levels associated with lower blood pressure
Caro, et al. [36] 2012 219 41.5 ± 13.9 29.2 ± 10.6 113.2 ± 13.1 73.3 ± 9.7 No association between 25(OH)D and HTN
Margolis, et al. [37] 2008 36,282 62 ± 7 - - - No association between 25(OH)D and HTN
Li, et al. [38] 2012 1,420 - - - - No association between 25(OH)D and HTN
Kashi, et al. [39] 2004 251 50 ± 8 - - - No association between 25(OH)D and HTN

Conclusions

Hypertension is one of the most crucial chronic diseases, which can cause many other cardiovascular disorders and eventually may lead to death. This article reviews whether serum Vitamin D concentration plays an important role in causing hypertension or not. Because of the opposing consequences of different reviews on the role of Vitamin D in preventing hypertension development or its treatment, it appears that Vitamin D levels in the body modulate the blood pressure indirectly. More studies should be conducted after eliminating the compounding factors in order to prove the association. We suggest that physicians should keep a check on the Vitamin D levels of their patients in order to curb the ever-increasing incidence of hypertension.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

  • 1.Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Murray CJL, Lopez AD. Lancet. 1997;349:1436–1442. doi: 10.1016/S0140-6736(96)07495-8. [DOI] [PubMed] [Google Scholar]
  • 2.Long-term high-salt diet causes hypertension and decreases renal expression of vascular endothelial growth factor in Sprague-Dawley rats. Gu JW, Bailey AP, Tan W, Shparago M, Young E. J Am Soc Hypertens. 2008;2:275–285. doi: 10.1016/j.jash.2008.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Global burden of hypertension: analysis of worldwide data. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. http://www.sciencedirect.com/science/article/pii/S0140673605177411. Lancet. 2005;365:217–223. doi: 10.1016/S0140-6736(05)17741-1. [DOI] [PubMed] [Google Scholar]
  • 4.Haghdoost AA, Sadeghirad B, Rezazadehkermani M. Arch Iran Med. Vol. 11. Jul: [Mar;2017 ]. 2008. Epidemiology and heterogeneity of hypertension in Iran: a systematic review; pp. 444–452. [PubMed] [Google Scholar]
  • 5.Victor RG. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th ed. Vol. 43. Philadelphia, PA: Saunders; 2014. Systemic Hypertension: Mechanisms and Diagnosis; pp. 934–952. [Google Scholar]
  • 6.Hypertension and pre-hypertension: Prevalence, awareness and management among Iranian adults older than 20 years (Article in Persian) Delavari A, Horri B, Alikhani S, Mahdavi A, Hosseini SM, Haghighi S. http://en.journals.sid.ir/ViewPaper.aspx?ID=68320 J Med Council Islamic Rep Iran. 2007;24:372–380. [Google Scholar]
  • 7.Chobanian AV. N Engl J Med. Vol. 345. Saunders; 2001. Control of hypertension--an important national priority; pp. 534–535. [DOI] [PubMed] [Google Scholar]
  • 8.1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151055/ J Clin Invest. 2002;110:229–238. doi: 10.1172/JCI15219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Vaidya A, Williams JS. http://www.metabolismjournal.com/article/S0026-0495(11)00303-9/fulltext. Metabolism. 2012;61:450–458. doi: 10.1016/j.metabol.2011.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. J Steroid Biochem Mol Biol. 2004;89-90:387–392. doi: 10.1016/j.jsbmb.2004.03.004. [DOI] [PubMed] [Google Scholar]
  • 11.Vitamin D, blood pressure, and African Americans: toward a unifying hypothesis. Rostand SG. Clin J Am Soc Nephrol. 2010;5:1697–1703. doi: 10.2215/CJN.02960410. [DOI] [PubMed] [Google Scholar]
  • 12.Racial disparity in blood pressure: is vitamin D a factor? Fiscella K, Winters P, Tancredi D, Franks P. J Gen Intern Med. 2011;26:1105–1111. doi: 10.1007/s11606-011-1707-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ultraviolet B and blood pressure. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Lancet. 1998;352:709–710. doi: 10.1016/S0140-6736(05)60827-6. [DOI] [PubMed] [Google Scholar]
  • 14.Emergence of new risk factors for causing hypertension. Mehta V. http://jmri.org.in/index.php/jmri/article/view/4/5 J Med Res Innov. 2017;1:9–11. [Google Scholar]
  • 15.Vitamin D metabolism, mechanism of action, and clinical applications. Bikle DD. Chem Biol. 2014;21:319–329. doi: 10.1016/j.chembiol.2013.12.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Expression of the vitamin d receptor is increased in the hypertrophic heart. Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M, Law CS, Gardner DG. Hypertension. 2008;52:1106–1112. doi: 10.1161/HYPERTENSIONAHA.108.119602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. Handel AE, Sandve GK, Disanto G, Berlanga-Taylor AJ, Gallone G, Hanwell H, Drabløs F, Giovannoni G, Ebers GC, Ramagopalan SV. BMC Med. 2013;11:163. doi: 10.1186/1741-7015-11-163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, et al. J Clin Invest. 1989;83:1903–1915. doi: 10.1172/JCI114097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. Mitsuhashi T, Morris RC Jr, Ives HE. J Clin Invest. 1991;87:1889–1895. doi: 10.1172/JCI115213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Vitamin D-dependent suppression of human atrial natriuretic peptide gene promoter activity requires heterodimer assembly. Chen S, Costa CH, Nakamura K, Ribeiro RC, Gardner DG. J Biol Chem. 1999;274:11260–11266. doi: 10.1074/jbc.274.16.11260. [DOI] [PubMed] [Google Scholar]
  • 21.Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Chen S, Wu J, Hsieh JC, Whitfield GK, Jurutka PW, Haussler MR, Gardner DG. Hypertension. 1998;31:1338–1342. doi: 10.1161/01.hyp.31.6.1338. [DOI] [PubMed] [Google Scholar]
  • 22.Coactivator-vitamin D receptor interactions mediate inhibition of the atrial natriuretic peptide promoter. Chen S, Cui J, Nakamura K, Ribeiro RC, West BL, Gardner DG. J Biol Chem. 2000;275:15039–15048. doi: 10.1074/jbc.275.20.15039. [DOI] [PubMed] [Google Scholar]
  • 23.Corepressors (NCoR and SMRT) as well as coactivators are recruited to positively regulated 1α,25-dihydroxyvitamin D3-responsive genes. Meyer MB, Pike JW. J Steroid Biochem Mol Biol. 2013;136:120–124. doi: 10.1016/j.jsbmb.2012.08.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Circulation. 2011;124:1838–1847. doi: 10.1161/CIRCULATIONAHA.111.032680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. J Clin Invest. 2002;110:229–238. doi: 10.1172/JCI15219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Renin-angiotensin system activity in vitamin D deficient, obese individuals with hypertension: An urban Indian study. Kota SK, Kota SK, Jammula S, Meher LK, Panda S, Tripathy PR, Modi KD. Indian J Endocrinol Metab. 2011;15:0–401. doi: 10.4103/2230-8210.86985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Does vitamin d deficiency cause hypertension? Current evidence from clinical studies and potential mechanisms. Ullah MI, Uwaifo GI, Nicholas WC, Koch CA. Int J Endocrinol. 2010;2010:579640. doi: 10.1155/2010/579640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Kunutsor SK, Apekey TA, Steur M. Eur J Epidemiol. 2013;28:205–221. doi: 10.1007/s10654-013-9790-2. [DOI] [PubMed] [Google Scholar]
  • 29.Effect of vitamin D on blood pressure: a systematic review and meta-analysis. Witham MD, Nadir MA, Struthers AD. J Hypertens. 2009;27:1948–1954. doi: 10.1097/HJH.0b013e32832f075b. [DOI] [PubMed] [Google Scholar]
  • 30.Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Hypertension. 2010;55:792–798. doi: 10.1161/HYPERTENSIONAHA.109.143990. [DOI] [PubMed] [Google Scholar]
  • 31.Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Hypertension. 2007;49:1063–1069. doi: 10.1161/HYPERTENSIONAHA.107.087288. [DOI] [PubMed] [Google Scholar]
  • 32.Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Am J Hypertens. 2012;25:1215–1222. doi: 10.1038/ajh.2012.111. [DOI] [PubMed] [Google Scholar]
  • 33.Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A, Ghiadoni L, Taddei S, Bernini G. J Renin Angiotensin Aldosterone Syst. 2014;15:82–87. doi: 10.1177/1470320312471149. [DOI] [PubMed] [Google Scholar]
  • 34.Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Vimaleswaran KS, Cavadino A, Berry DJ; LifeLines Cohort Study investigators, Jorde R, Dieffenbach AK, Lu C, Alves AC, Heerspink HJ, Tikkanen E, Eriksson J, Wong A, Mangino M, Jablonski KA, Nolte IM, Houston DK, Ahluwalia TS, van der Most PJ, Pasko D, Zgaga L, Thiering E, Vitart V, Fraser RM, Huffman JE, de Boer RA, Schöttker B, Saum KU, McCarthy MI, Dupuis J, Herzig KH, Sebert S, Pouta A, Laitinen J, Kleber ME, Navis G, Lorentzon M, Jameson K, Arden N, Cooper JA, Acharya J, Hardy R, Raitakari O, Ripatti S, Billings LK, Lahti J, Osmond C, Penninx BW, Rejnmark L, Lohman KK, Paternoster L, Stolk RP, Hernandez DG, Byberg L, Hagström E, Melhus H, Ingelsson E, Mellström D, Ljunggren O, Tzoulaki I, McLachlan S, Theodoratou E, Tiesler CM, Jula A, Navarro P, Wright AF, Polasek O; International Consortium for Blood Pressure (ICBP); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium; Global Blood Pressure Genetics (Global BPGen) consortium; Caroline Hayward, Wilson JF, Rudan I, Salomaa V, Heinrich J, Campbell H, Price JF, Karlsson M, Lind L, Michaëlsson K, Bandinelli S, Frayling TM, Hartman CA, Sørensen TI, Kritchevsky SB, Langdahl BL, Eriksson JG, Florez JC, Spector TD, Lehtimäki T, Kuh D, Humphries SE, Cooper C, Ohlsson C, März W, de Borst MH, Kumari M, Kivimaki M, Wang TJ, Power C, Brenner H, Grimnes G, van der Harst P, Snieder H, Hingorani AD, Pilz S, Whittaker JC, Järvelin MR, Hyppönen E. Lancet Diabetes Endocrinol. 2014;2:719–729. doi: 10.1016/S2213-8587(14)70113-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Low vitamin D and hypertension: a causal association? Afzal S, Nordestgaard BG. Lancet Diabetes Endocrinol. 2014;2:682–684. doi: 10.1016/S2213-8587(14)70119-6. [DOI] [PubMed] [Google Scholar]
  • 36.Association between vitamin D levels and blood pressure in a group of Puerto Ricans. Caro Y, Negrón V, Palacios C. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700354/ P R Health Sci J. 2012;31:123–129. [PMC free article] [PubMed] [Google Scholar]
  • 37.Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm RH Jr, Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC; Women's Health Initiative Investigators. Hypertension. 2008;52:847–855. doi: 10.1161/HYPERTENSIONAHA.108.114991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vitamin D, parathyroid hormone and their associations with hypertension in a Chinese population. Li L, Yin X, Yao C, Zhu X, Wu X. PloS one. 2012;7:0. doi: 10.1371/journal.pone.0043344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Association of blood pressure, serum vitamin D, calcium and PTH in individuals over 40 in East Tehran. Kashi Z, Mirmiran P, Mehrabi Y, Hedayati M, Azizi F. http://ijem.sbmu.ac.ir/article-1-261-en.html IJEM. 2004;5:261–270. [Google Scholar]
  • 40.Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ, Dekker JM, van Dam RM. J Intern Med. 2007;261:558–565. doi: 10.1111/j.1365-2796.2007.01778.x. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES